Dharwad News Today

Propulsion of Follicular Lymphoma Clinical Trial Pipeline as Novel and Extensive 50+ Therapies Likely to Enter in the Domain | DelveInsight

 Breaking News
  • No posts were found

Propulsion of Follicular Lymphoma Clinical Trial Pipeline as Novel and Extensive 50+ Therapies Likely to Enter in the Domain | DelveInsight

August 24
21:20 2023
Propulsion of Follicular Lymphoma Clinical Trial Pipeline as Novel and Extensive 50+ Therapies Likely to Enter in the Domain | DelveInsight

(Albany, United States) As per DelveInsight’s assessment, globally, the Follicular Lymphoma Pipeline constitutes 50+ key companies continuously working towards developing 50+ Follicular Lymphoma Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the Follicular Lymphoma Pipeline Report, a detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Follicular Lymphoma NDA approvals (if any), and product development activities comprising the technology, Follicular Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

To explore more information on the latest breakthroughs in the Follicular Lymphoma Pipeline treatment landscape of the report, click here @ Follicular Lymphoma Pipeline Outlook

 

Key Takeaways from the Follicular Lymphoma Pipeline Report

  • DelveInsight’s Follicular Lymphoma Pipeline analysis depicts a robust space with 50+ active players working to develop 50+ pipeline treatment therapies.
  • The leading companies working in the Follicular Lymphoma Market include Incyte Corporation, Genmab A/S, BeiGene, Merck & Co., ADC Therapeutics, Xynomic Pharmaceuticals, Nordic Nanovector, TG Therapeutics Inc., Allogene Therapeutics, MEI Pharma, Innovent Biologics, and others.
  • Promising Follicular Lymphoma Pipeline Therapies in the various stages of development include DRL_RI (Proposed rituximab biosimilar), MabThera®, Epcoritamab, Rituximab, Lenalidomide, and others.
  • On August 2023, AbbVie announced a study of phase 3 clinical trials for Epcoritamab, Rituximab, and Lenalidomide. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
  • On August 2023, Celgene announced a study of phase 3 clinical trias for Rituximab and Lenalidomide. The purpose of this study is to evaluate the effect of the combined treatment of lenalidomide and rituximab in controlling the Follicular Lymphoma disease and also increase the length of response compared to the available standard combination chemotherapy treatment for Follicular Lymphoma.

 

Follicular Lymphoma Overview

A follicular lymphoma is a form of cancer. It is a type of non-Hodgkin lymphoma (NHL), which is a group of related cancers that affect the lymphatic system (lymphomas). The lymphatic system functions as part of the immune system and helps to protect the body against infection and disease.

 

For further information, refer to the detailed Follicular Lymphoma Unmet Needs, click here for Follicular Lymphoma Ongoing Clinical Trial Analysis

 

Follicular Lymphoma Emerging Drugs Profile

 

  • Tafasitamab: Incyte Corporation

Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb® engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). The drug currently investigated in Phase III trials for the condition.

 

  • Epcoritamab: Genmab A/S

Epcoritamab (DuoBody®-CD3xCD20) is a proprietary bispecific antibody created using Genmab’s DuoBody® technology, jointly owned by Genmab and AbbVie Inc. It targets CD20 on the B-cells, a clinically well-validated target that is expressed in a wide variety of B-cell malignancies. Epcoritamab (DuoBody®-CD3xCD20) is currently under investigation in multiple ongoing clinical studies including a Phase III study for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and follicular Lymphoma.

 

  • Zanubrutinib – BeiGene

Zanubrutinib (BGB-3111) — a small molecule inhibitor of Bruton’s tyrosine kinase, or BTK, that is currently being evaluated in a broad late-stage clinical trials program globally, including in China, as a potential monotherapy and in combination with other therapies to treat various B cell malignancies. BTK is a key component of the B-cell receptor, or BCR, signaling pathway and is an important regulator of cell proliferation and cell survival in various B cell malignancies. BTK inhibitors block BCR-induced BTK activation and its downstream signaling, leading to growth inhibition and cell death in certain malignant white blood cells called B-cells. Zanubrutinib is an orally active inhibitor that covalently binds to BTK, resulting in irreversible inactivation of the enzyme. The drug is currently under Phase III trial of the disease.

 

  • Pembrolizumab: Merck & Co.

Pembrolizumab is a monoclnal antibody that binds to and blocks PD-1 located on lymphocytes. This receptor is generally responsible for preventing the immune system from attacking the body’s own tissues; it is a so-called immune checkpoint. Normally, the PD-1 receptor on activated T-cells binds to ligands PD-L1 or PD-L2 on other cells, deactivating a potential T-cell-mediated immune response against normal cells in the body. Currently, it is in Phase II stage of development to treat Follicular lymphoma.

 

Follicular Lymphoma Pipeline Therapeutics Assessment

There are approx. 50+ key companies which are developing the therapies for Follicular Lymphoma. The Follicular Lymphoma companies which have their Follicular Lymphoma drug candidates in the most advanced stage, i.e. phase III.

 

Request a sample and discover the recent advances in Follicular Lymphoma Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Follicular Lymphoma Segmentation

 

Follicular Lymphoma Drugs and Companies

  • Epcoritamab: AbbVie
  • Lenalidomide: Genmab
  • Venetoclax: Hoffmann-La Roche

 

Follicular Lymphoma Therapeutics Assessment

  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

 

Some of the Companies in the Follicular Lymphoma Therapeutics Market include-

Incyte Corporation, Genmab A/S, BeiGene, Merck & Co., ADC Therapeutics, Xynomic Pharmaceuticals, Nordic Nanovector, TG Therapeutics Inc., Allogene Therapeutics, MEI Pharma, Innovent Biologics, and others.

 

Dive deep into rich insights for drugs for Follicular Lymphoma Pipeline, click here @ Follicular Lymphoma Unmet Needs and Analyst Views

 

Scope of the Follicular Lymphoma Pipeline Report

  • Coverage- Global
  • Companies- Incyte Corporation, Genmab A/S, BeiGene, Merck & Co., ADC Therapeutics, Xynomic Pharmaceuticals, Nordic Nanovector, TG Therapeutics Inc., Allogene Therapeutics, MEI Pharma, Innovent Biologics, and others.
  • Therapies- DRL_RI (Proposed rituximab biosimilar), MabThera®, Epcoritamab, Rituximab, Lenalidomide, and others.
  • Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Follicular Lymphoma Merger and acquisitions, Licensing Activities

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Follicular Lymphoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Follicular Lymphoma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Zanubrutinib – BeiGene
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Pembrolizumab: Merck & Co.
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Drug Name: Company Name
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Follicular Lymphoma Key Companies
  21. Follicular Lymphoma Key Products
  22. Follicular Lymphoma- Unmet Needs
  23. Follicular Lymphoma- Market Drivers and Barriers
  24. Follicular Lymphoma- Future Perspectives and Conclusion
  25. Follicular Lymphoma Analyst Views
  26. Follicular Lymphoma Key Companies
  27. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services